At Alimera Sciences, we are dedicated to developing innovative, vision-improving treatments for diseases of the retina. Our commitment to retina specialists and their patients is manifest in our development portfolio, studying compounds to treat early- and late-stage diseases such as diabetic macular edema, wet and dry age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
Today, our primary focus is on ILUVIEN®, a tiny, cylindrical polyimide tube that contains 190 µg of fluocinolone acetonide (FAc), a corticosteroid with a history of treating ocular diseases. Learn more >>
ILUVIEN® has received its marketing authorization approval in Austria, France, Germany, Italy, Portugal, Spain and the United Kingdom.
Alimera has received a positive outcome of the Repeat-Use Procedure for ILUVIEN® for the treatment of chronic diabetic macular edema (DME) in an additional 10 European Union countries. The regulatory process for these additional countries, consisting of Ireland, the Netherlands, Belgium, Luxembourg, Sweden, Denmark, Finland, Norway, Poland and the Czech Republic, will now enter the national phase in which each country grants marketing authorization. Alimera Sciences is still seeking approval in the United States.
The proposed treatment consists of a tiny, cylindrical polymide tube that contains 190 µg of fluocinolone acetonide (FAc), a corticosteroid. Corticosteroids have a history of treating ocular diseases. Learn More
In addition to activities related to the development of ILUVIEN, we are researching the effectiveness of NADPH (Nicotinamide Adenine Dinucleotide Phosphate) oxidase inhibitors. Learn more >>